98%
921
2 minutes
20
Introduction: Supported self-management empowering people with asthma to detect early deterioration and take timely action reduces the risk of asthma attacks. Smartphones and smart monitoring devices coupled with machine learning could enhance self-management by predicting asthma attacks and providing tailored feedback.We aim to develop and assess the feasibility of an asthma attack predictor system based on data collected from a range of smart devices.
Methods And Analysis: A two-phase, 7-month observational study to collect data about asthma status using three smart monitoring devices, and daily symptom questionnaires. We will recruit up to 100 people via social media and from a severe asthma clinic, who are at risk of attacks and who use a pressurised metered dose relief inhaler (that fits the smart inhaler device).Following a preliminary month of daily symptom questionnaires, 30 participants able to comply with regular monitoring will complete 6 months of using smart devices (smart peak flow meter, smart inhaler and smartwatch) and daily questionnaires to monitor asthma status. The feasibility of this monitoring will be measured by the percentage of task completion. The occurrence of asthma attacks (definition: American Thoracic Society/European Respiratory Society Task Force 2009) will be detected by self-reported use (or increased use) of oral corticosteroids. Monitoring data will be analysed to identify predictors of asthma attacks. At the end of the monitoring, we will assess users' perspectives on acceptability and utility of the system with an exit questionnaire.
Ethics And Dissemination: Ethics approval was provided by the East of England - Cambridge Central Research Ethics Committee. IRAS project ID: 285 505 with governance approval from ACCORD (Academic and Clinical Central Office for Research and Development), project number: AC20145. The study sponsor is ACCORD, the University of Edinburgh.Results will be reported through peer-reviewed publications, abstracts and conference posters. Public dissemination will be centred around blogs and social media from the Asthma UK network and shared with study participants.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535155 | PMC |
http://dx.doi.org/10.1136/bmjopen-2022-064166 | DOI Listing |
Cureus
August 2025
Department of Internal Medicine, University at Buffalo, Buffalo, USA.
Asthma is one of the most prevalent chronic respiratory illnesses, significantly impacting patients through shortness of breath and even death. Acute exacerbations are usually controlled with a short-acting beta agonist, such as an albuterol inhaler, as well as long-acting agents to prevent the occurrence of exacerbations and status asthmaticus. Status asthmaticus is an emergent episode of asthma that is refractory to standard treatment.
View Article and Find Full Text PDFFront Pediatr
August 2025
Paediatric Emergency Department, Ezkerraldea-Enkarterri-Cruces Integrated Health Organization, Cruces University Hospital, Basque Health Service-Osakidetza, Barakaldo, Spain.
Introduction: This study aims to evaluate the effectiveness and feasibility of the implementation of an Asthma Integrated Care Pathway (AICP) to improve care and reduce variability according to recommended clinical practice guidelines, for children presenting with acute asthma episodes in paediatric primary care, and hospital services including emergency departments.
Methods And Analysis: A cluster quasi-experimental implementation trial with a matched control group will be launched in a regional healthcare service. All the paediatric healthcare professionals providing care in two health districts (HDs) will receive interventions over two 12-month periods during which components of the implementation strategy to favour adoption of the AICP will be deployed cumulatively.
Eur Ann Allergy Clin Immunol
September 2025
Allergology Unit, San Carlo Clinic, Paderno Dugnano, Milan, Italy.
Chronic spontaneous urticaria (CSU) is a common disorder characterized by the recurrence of wheals and/or angioedema for more than 6 weeks. About 35% of patients experience wheals and angioedema (AE-CSU) and around 6% of patients only present angioedema, also known as chronic histaminergic angioedema (CHA). As few data comparing CHA and AE-CSU are published, we analyzed the differences between demographic and clinical characteristics of these populations.
View Article and Find Full Text PDFJ Allergy Clin Immunol Pract
August 2025
Institute of Allergology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universitätsmedizin Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany. Electronic a
Background: Poor compliance with hereditary angioedema guidelines for on-demand treatment is common due to challenges with parenteral administration. Sebetralstat, an oral plasma kallikrein inhibitor, demonstrated faster times to beginning of symptom relief, reduction in attack severity, and complete resolution than placebo in the phase 3 KONFIDENT trial (NCT05259917).
Objective: This analysis evaluated long-term safety and effectiveness of sebetralstat in KONFIDENT-S (NCT05505916), an ongoing, 2-year, open-label extension study.
Leg Med (Tokyo)
August 2025
Department of Legal Medicine, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3 Asahi-machi, Abeno, Osaka 545-8585, Japan.
We report a case of death due to thallium (Tl) poisoning and discuss the findings with reference to the literature on Tl poisoning. A woman in her 20 s with a history of asthma developed symptoms such as coughing, vomiting, and fatigue, and visited a primary-care physician. She was rushed to another hospital on suspicion of an asthma attack, but her condition suddenly worsened and she died 3 days later.
View Article and Find Full Text PDF